glp 1 agonists for type 2 diabetes New Developments in Pharmacological Treatment of Obesity and Diabetes—Beyond and within GLP-1 Receptor Mapping the effectiveness and risks
Description
Important observations All five clinical trials that were included in the analysis reported GLP-1 receptor agonist-mediated reduction in substance use disorder, with two trials respectively reporting a significant therapeutic impact of GLP-1 receptor agonist in reducing alcohol use disorder and nicotine use disorder
[DOI] [PubMed] [Google Scholar] 124.Kendall DM, Riddle MC, Rosenstock J, Zhuang D, Kim DD, Fineman MS, Baron AD
It will reduce from $504 to $201
10.2337/dc15-2479
The data also shows that people living with obesity paid more annually in medical costs than their lighter counterparts ($3,097 versus $1,861 per person), totaling $173 billion in medical expenditures
